Host Immunity in COVID 19
This e-learning Session will discuss the immune mechanisms that play a role in COVID-19 as well as the role of serologic testing for diagnostic purposes. The potential of immunomodulatory treatments currently in clinical trials will be assessed.
- To discuss the assessment of the high-risk patient in terms of impaired host defense (either due to decreased antiviral immunity or due to hyper-inflammatory phenotype)
- To discuss how the use of CRP may be used to identify high-risk patients
- To highlight how the empiric off-label immunomodulator use in high-risk patients may decrease burden on healthcare system
|Partner Organisation/Institution||National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health|
|Medical Association of Malta as representative of UEMS||0.5 Credits|
|Malta College of Family Doctors||0.5 Credits|